Wednesday, Apr 9, 1997
South San Francisco, Calif. -- April 9, 1997 --Genentech, Inc. (NYSE: GNE) today announced that the U.S. Patent Office has granted Genentech U.S. Patents numbered 5,618,788 and 5,618,789 for methods of treating hemophiliacs with recombinant human Factor VIII and recombinant human Factor VIII as a pharmaceutical product, respectively. A corresponding European patent was granted in 1991 and was unopposed. Genentech continues to receive royalties on the recombinant human Factor VIII product.
"We are very pleased by the issuance of these important patents to Genentech and especially by the contribution that our work in making available recombinant human Factor VIII has had to the lives of patients with hemophilia," said Janet Hasak, Genentech's manager of Patent Prosecution and Trademarks.
The patents are based upon applications filed with the U.S. Patent and Trademark Office in April 1984. The new patent 5,618,788 was involved in a three-way interference with U.S. patent applications assigned to Chiron Corporation and Genetics Institute, Inc.
The U.S. Board of Patent Appeals and Interferences determined Genentech inventors were first to invent the subject matter claimed in the interference. The new patents are within the scope of the license agreement Genentech entered into in late 1984 with Miles Laboratories, Inc., Cutter Group, a wholly owned subsidiary of Bayer AG. The agreement gave Miles an exclusive right to manufacture, use and sell recombinant human Factor VIII worldwide. Subsequently, Miles sublicensed non-exclusively part of its rights through agreements with Baxter Healthcare Corporation and Genetics Institute. Rhone-Poulenc Rorer, Inc. was granted distribution rights.
Genentech is a leading biotechnology company that discovers, develops, manufactures, and markets human pharmaceuticals for significant unmet medical needs. Eleven of the currently marketed biotechnology products stem from Genentech science, six of which Genentech markets directly in the United States. The company has headquarters in South San Francisco, California, and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.
# # #